Kiniksa Pharmaceuticals International plc.

Filed a patent for "treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein" on Thu, December 29, 2022

Filed a patent for "treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein" on Thu, January 19, 2023

Filed a patent for "pharmaceutical composition of a humanized anti-cd40 antibody" on Thu, June 29, 2023

Filed a patent for "pharmaceutical compositions of humanized anti-cd40 antibodies" on Thu, September 7, 2023

Filed a patent for "pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof" on Thu, June 15, 2023

Filed a patent for "methods of treating or reducing risk of transplant rejection" on Thu, September 14, 2023

Filed a patent for "treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein" on Thu, November 2, 2023

Filed a patent for "methods of treating or reducing risk of transplant rejection" on Wed, April 6, 2022

Filed a patent for "humanized anti-cd40 antibodies and uses thereof" on Thu, December 8, 2022